GSK2190915_sodium_salt_SDS_MedChemExpress

合集下载

USP38-通用章节目录

USP38-通用章节目录

USP38-通用章节(zhāngjié)目录USP38-通用章节(zhāngjié)目录Guide to General Chapters 通用(tōngyòng)章节指导General Requirements for Test and Assays检查(jiǎnchá)与含量(hánliàng)分析的一般(yībān)要求<1>INJECTIONS AND IMPLANTED DRUG PRODUCTS (PARENTERALS)—PRODUCT QUALITY TESTS 注射和植入药物(yàowù)产品(注射用) —产品质量测试<1>INJECTIONS注射剂<2>ORAL DRUG PRODUCTS—PRODUCT QUALITY TESTS 口服药物产品质量测试<3>TOPICAL AND TRANSDERMAL DRUG PRODUCTS—PRODUCT QUALITY TESTS 局部和透皮药物产品—产品质量测试<4>MUCOSAL DRUG PRODUCTS—PRODUCT QUALITY TESTS 粘膜药物产品质量测试<5>INHALATION AND NASAL DRUG PRODUCTS—GENERAL INFORMATION AND PRODUCT QUALITY TESTS 吸入剂产品—产品质量测试<7>LABELING 标签<11>USP REFERENCE STANDARDS USP标准品Apparatus for Test and Assays用于检查与含量分析的器具<17>PRESCRIPTION CONTAINER LABELING处方容器(róngqì)标签<21>THERMOMETERS温度计<31>VOLUMETRIC APPARATUS容量(róngliàng)器具<41>BALANCES天平(tiānpíng)Microbiological Tests 微生物检查法<51>ANTIMICROBIAL EFFECTIVENESS TESTING抗菌剂有效性检查法<55>BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS生物(shēngwù)指示剂-耐药性实验(shíyàn)<61>MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS非无菌产品的微生物限度检查:微生物列举检查法<62>MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR SPECIFIED MICROORGANISMS 非无菌产品的微生物限度检查:特定微生物检查法<63>MYCOPLASMA TESTS 支原体检查法<71>STERILITY TESTS无菌检查法Biological tests and assays生物检查法与测定法<81>ANTIBIOTICS—MICROBIAL ASSAYS抗生素-微生物测定(cèdìng)<85>BACTERIAL ENDOTOXINS TEST细菌(xìjūn)内毒素检查法<87>BIOLOGICAL REACTIVITY TESTS, IN VITRO体外的生物(shēngwù)反应性检查法<88>BIOLOGICAL REACTIVITY TESTS, IN VIVO 体内(tǐ nèi)的生物反应性检查法<89>ENZYMES USED AS ANCILLARY MATERIALS IN PHARMACEUTICAL MANUFACTURING药品(yàopǐn)生产中酶作为辅料所使用<90>FETAL BOVINE SERUM—QUALITY ATTRIBUTES AND FUNCTIONALITY TESTS 牛胎儿血清-质量品质和功能检查法<91>CALCIUM PANTOTHENATE ASSAY泛酸钙测定法<92>GROWTH FACTORS AND CYTOKINES USED IN CELL THERAPY MANUFACTURING 在细胞疗法中使用生长因子和细胞因子<111>DESIGN AND ANALYSIS OF BIOLOGICAL ASSAYS 生物测定法的设计与分析<115>DEXPANTHENOL ASSAY右泛醇(拟胆碱(d ǎn jiǎn)药)测定法<121>INSULIN ASSAYS胰岛素测定法<121.1>PHYSICOCHEMICAL ANALYTICAL PROCEDURES FOR INSULINS胰岛素的物理化学(wù lǐ huà xué)分析程序<123>GLUCAGON BIOIDENTITY TESTS 高血糖素的生物(shēngwù)鉴别检查法<124>ERYTHROPOIETIN BIOASSAYS 红细胞生成素的微生物测定(cèdìng)<126>SOMATROPIN BIOIDENTITY TESTS 生长激素(shēnɡ chánɡ jī sù)的生物鉴别检查法<130>PROTEIN A QUALITY ATTRIBUTES 蛋白质A的质量特征<151>PYROGEN TEST热原检查法<161>TRANSFUSION AND INFUSION ASSEMBLIES AND SIMILAR MEDICAL DEVICES 输血输液用具以及相类似的医疗器械<171>VITAMIN B12 ACTIVITY ASSAY……2548维生素B12活性测定法Chemical Tests and assays化学实验检查与测定法鉴别检查<181>IDENTIFICATION—ORGANIC NITROGENOUS BASES鉴别(jiànbié)-有机氮碱化合物<191>IDENTIFICATION TESTS—GENERAL鉴别实验(shíyàn)-通用<193>IDENTIFICATION—TETRACYCLINES鉴别(jiànbié)-四环素类<197>SPECTROPHOTOMETRIC IDENTIFICATION TESTS分光(fēn ɡuānɡ)光度计鉴别实验(shíyàn)<201>THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST薄层色谱鉴别实验Limit Tests 限度检查法<206>ALUMINUM铝<207>TEST FOR 1,6-ANHYDRO DERIVATIVE FOR ENOXAPARIN SODIUM依诺肝素钠的酐类衍生物实验<208>ANTI-FACTOR Xa AND ANTI-FACTOR IIa ASSAYS FOR UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS普通肝素和低分子肝素产品中抗体Xa和抗体IIa测定<209>LOW MOLECULAR WEIGHT HEPARIN MOLECULAR WEIGHT DETERMINATIONS低分子(fēnzǐ)肝素钠分子量测定<211>ARSENIC砷<221>CHLORIDE AND SULFATE氯和硫<223>DIMETHYLANILINE二甲基苯胺<226>4-EPIANHYDRO-TETRACYCLINE4-?-四环素<227>4-AMINOPHENOL IN ACETAMINOPHEN-CONTAINING DRUG PRODUCTS对乙酰氨酚药物产品(chǎnpǐn)中氨基酚<228>ETHYLENE OXIDE AND DIOXANE 环氧乙烷和二氧六环<231>HEAVY METALS重金属(删除(shānchú))<232>ELEMENTAL IMPURITIES—LIMITS 元素(yuán sù)杂质-限度(xiàndù)<233>ELEMENTAL IMPURITIES—PROCEDURES 元素杂质-规程<241>IRON铁<251>LEAD铅<261>MERCURY汞<267>POROSIMETRY BY MERCURY INTRUSION 水银(shuǐyín)孔隙仪<268>POROSITY BY NITROGEN ADSORPTION–DESORPTION 氮吸附(xīfù)-解吸测定孔隙率<271>READILY CARBONIZABLE SUBSTANCES TEST易碳化物检查法<281>RESIDUE ON IGNITION炽灼(chì zhuó)残渣(cán zhā)<291>SELENIUM硒Other Tests and Assays 其它(qítā)检查法与测定法<301>ACID-NEUTRALIZING CAPACITY酸中和容量<311>ALGINATES ASSAY藻酸盐测定法<341>ANTIMICROBIAL AGENTS—CONTENT 抗菌剂-含量<345>Assay for Citric Acid/Citrate and Phosphate 柠檬酸/柠檬酸盐和磷酸盐的测定<351>ASSAY FOR STEROIDS类固醇(甾类化合物)测定法<361> BARBITURATE ASSAY 巴比妥类药物测定法<371>COBALAMIN RADIOTRACER ASSAY钴铵素放射性跟踪剂测定法<381>ELASTOMERIC CLOSURES FOR INJECTIONS 注射剂的弹性(tánxìng)密封件<391>EPINEPHRINE ASSAY肾上腺素测定法<401>FATS AND FIXED OILS脂肪(zhīfáng)与混合油<411>FOLIC ACID ASSAY叶酸(yè suān)测定法<413>IMPURITIES TESTING IN MEDICAL GASES 医用气体(qìtǐ)杂质检查<415>MEDICAL GASES ASSAY 医用气体含量(hánliàng)检查<425>IODOMETRIC ASSAY—ANTIBIOTICS碘量检查法-抗生素<429>LIGHT DIFFRACTION MEASUREMENT OF PARTICLE SIZE粒径的光衍射测量法<431>METHOXY DETERMINATION甲氧基测定法<441>NIACIN OR NIACINAMIDE ASSAY 烟酰或烟酰胺测定法<451>NITRITE TITRATION亚硝酸盐滴定<461>NITROGEN DETERMINATION氮测定法<466>ORDINARY IMPURITIES一般杂质<467>RESIDUAL SOLVENTS残留溶剂<469>ETHYLENE GLYCOL, DIETHYLENEGLYCOL, AND TRIETHYLENE GLYCOLIN ETHOXYLATED SUBSTANCES 乙氧基物质(wùzhì)中乙二醇、二甘醇、三甘醇测定<471>OXYGEN FLASK COMBUSTION氧瓶燃烧(ránshāo)法<481>RIBOFLAVIN ASSAY核黄素(维生素B2)测定法<501>SALTS OF ORGANIC NITROGENOUS BASES有机(yǒujī)氮盐<503>ACETIC ACID IN PEPTIDES 多肽(duō tài)类中乙酸测定<511>SINGLE-STEROID ASSAY单一(dānyī)的类固醇测定法<525>SULFUR DIOXIDE 二氧化硫<531>THIAMINE ASSAY硫胺素测定法<541>TITRIMETRY滴定法<551>VITAMIN E ASSAY维生素E测定法<561>ARTICLES OF BOTANICAL ORIGIN植物起源的药品<563>IDENTIFICATION OF ARTICLES OF BOTANICAL ORIGIN植物药品的鉴别<565>BOTANICAL EXTRACTS植物(zhíwù)提取<571>VITAMIN A ASSAY维生素A测定法<581>VITAMIN D ASSAY维生素D测定法<591>ZINC DETERMINATION锌的测定法Physical Test and Determinations物理(wùlǐ)检查(jiǎnchá)与测定法<601>INHALATION AND NASAL DRUGPRODUCTS: AEROSOLS, SPRAYS, ANDPOWDERS—PERFORMANCE QUALITYTESTS吸入剂、鼻雾剂:气溶胶,喷雾,干粉(gānfěn)-质量(zhìliàng)通则<602>PROPELLANTS 推进剂<603>TOPICAL AEROSOLS 局部喷雾剂<604>LEAK RATE 渗漏率<610>ALTERNATIVE MICROBIOLOGICAL SAMPLING METHODS FOR NONSTERILEINHALED AND NASAL PRODUCTS 非无菌吸入和鼻雾剂可供选择的微生物取样方法<611>ALCOHOL DETERMINATION乙醇测定法<616>BULK DENSITY AND TAPPED DENSITY堆密度与振实密度<621>CHROMATOGRAPHY色谱法<631>COLOR AND ACHROMICITY呈色与消色<641>COMPLETENESS OF SOLUTION溶解度<643>TOTAL ORGANIC CARBON总有机(yǒujī)碳<645>WATER CONDUCTIVITY水电导率<651>CONGEALING TEMPERATURE凝点温度(wēndù)<659>PACKAGING AND STORAGE REQUIREMENTS 包装和储藏(chǔcáng)要求<660>CONTAINERS—GLASS 容器(róngqì)-玻璃<661>CONTAINERS—PLASTICS容器(róngqì)-塑料<670>AUXILIARY PACKAGING COMPONENTS 辅助包装部件<671>CONTAINERS—PERFORMANCE TESTING 容器-性能测试<691>COTTON棉花<695>CRYSTALLINITY结晶度<696>CHARACTERIZATION OF CRYSTALLINE SOLIDS BY MICROCALORIMETRY AND SOLUTION CALORIMETRY 通过溶液量热学测定结晶性<697>CONTAINER CONTENT FOR INJECTIONS 注射剂容器容积<698>DELIVERABLE VOLUME抽取体积<699>DENSITY OF SOLIDS固体(gùtǐ)密度<701>DISINTEGRATION崩解(bēnɡ jiě)时限(shíxi àn)<705>QUALITY ATTRIBUTES OF TABLETS LABELED AS HAVING A FUNCTIONAL SCORE ?<711>DISSOLUTION 溶出度<721>DISTILLING RANGE馏程<724>DRUG RELEASE药物(yàowù)释放度<729>GLOBULE SIZE DISTRIBUTION IN LIPID INJECTABLE EMULSIONS脂类可注射(zhùshè)的乳剂的粒径分布<730>Plasma Spectrochemistry 血浆光谱化学?<731>LOSS ON DRYING4干燥失重<733>LOSS ON IGNITION灼烧失重<735>X-RAY FLUORESCENCE SPECTROMETRY X射线光谱<736>MASS SPECTROMETRY 质谱<741>MELTING RANGE OR TEMPERATURE熔距或熔点<751>METAL PARTICLES IN OPHTHALMIC OINTMENTS眼用软膏中的金属粒子<755>MINIMUM FILL最低装量<761>NUCLEAR MAGNETIC RESONANCE核磁共振(hé cíɡònɡ zhèn)<771>OPHTHALMIC OINTMENTS眼用软膏(ruǎngāo)<776>OPTICAL MICROSCOPY光学(guāngxué)显微镜<781>OPTICAL ROTATION旋光度<785>OSMOLALITY AND OSMOLARITY渗透压<786>PARTICLE SIZE DISTRIBUTION ESTIMATION BY ANALYTICAL SIEVING筛分(shāi fēn)法估算粒径分布(fēnbù)<787>SUBVISIBLE PARTICULATE MATTER IN THERAPEUTIC PROTEIN INJECTIONS显微计数法在治疗性蛋白注射剂中应用<788>PARTICULATE MATTER IN INJECTIONS注射剂中的不溶性微粒<789>PARTICULATE MATTER IN OPHTHALMIC SOLUTIONS眼用溶液中的不溶性微粒<790>VISIBLE PARTICULATES IN INJECTIONS 注射剂中可见异物<791>pH<795>PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS药物混合-非无菌制剂<797>PHARMACEUTICAL COMPOUNDING—STERILE PREPARATIONS药物混合(hùnhé)-无菌制剂<801>POLAROGRAPHY极谱法<811>POWDER FINENESS粉剂(fěn jì)细度<821>RADIOACTIVITY放射性<823>POSITRON EMISSION TOMOGRAPHY DRUGS FOR COMPOUNDING,INVESTIGATIONAL, AND RESEARCHUSES用于正电子发射(fāshè)断层造影(zàoyǐng)术的放射性药物(yàowù)<831>REFRACTIVE INDEX折光率<841>SPECIFIC GRAVITY比重<846>SPECIFIC SURFACE AREA 比表面积<851>SPECTROPHOTOMETRY AND LIGHT-SCATTERING分光光度计与光散射<852>ATOMIC ABSORPTION SPECTROSCOPY 原子吸收光谱<853>FLUORESCENCE SPECTROSCOPY 荧光光谱<854>MID-INFRARED SPECTROSCOPY 中红外光谱<857>ULTRAVIOLET-VISIBLE SPECTROSCOPY 紫外可见(kějiàn)光谱<861>SUTURES—DIAMETER缝线(fénɡ xiàn)-直径?<871>SUTURES—NEEDLE ATTACHMENT缝线(fénɡ xiàn)-穿孔(chuānkǒng)实验<881>TENSILE STRENGTH张力(zhānglì)<891>THERMAL ANALYSIS热分析<905>UNIFORMITY OF DOSAGE UNITS制剂单位的含量均匀度<911>VISCOSITY—CAPILLARY METHODS黏度-毛细管法<912>VISCOSITY—ROTATIONAL METHODS 黏度-旋转法<913>VISCOSITY—ROLLING BALL METHOD 黏度-球法<921>WATER DETERMINATION水分测定<941>CHARACTERIZATION OF CRYSTALLINE AND PARTIALLY CRYSTALLINE SOLIDSBY X-RAY POWDER DIFFRACTION (XRPD)X光衍射General Information通用信息<1005>ACOUSTIC EMISSION 声频发射<1010>ANALYTICAL DATA—INTERPRETATION AND TREATMENT分析数据(shùjù)-解释与处理<1015>AUTOMATED RADIOCHEMICAL SYNTHESIS APPARATUS放射性自动合成装置(zhuāngzhì)<1024>BOVINE SERUM 牛血清(xuèqīng)<1027>FLOW CYTOMETRY 流式细胞仪<1030>BIOLOGICAL ASSAY CHAPTERS—OVERVIEW AND GLOSSARY生物测定章节(zhāngjié)-综述和术语<1031>THE BIOCOMPATIBILITY OFMATERIALS USED IN DRUGCONTAINERS, MEDICAL DEVICES, ANDIMPLANTS用于药物容器(róngqì)、医疗设施和植入剂的材料的生物相容性<1034>ANALYSIS OF BIOLOGICAL ASSAYS 生物测定分析<1035>BIOLOGICAL INDICATORS FOR STERILIZATION灭菌用生物指示剂<1041>BIOLOGICS生物制剂<1043>Ancillary Material for Cell, Gene, and Tissue-Engineered Products细胞,基因与组织(zǔzhī)设计产品的辅助材料<1044>CRYOPRESERVATION OF CELLS 细胞低温(dīwēn)保存<1045>BIOTECHNOLOGY-DERIVED ARTICLES 生物(shēngwù)技术提取产品<1046>CELLULAR AND TISSUE-BASED PRODUCTS细胞(xìbāo)与组织(zǔzhī)产品<1047>GENE THERAPY PRODUCTS 基因治疗产品<1048>QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS OF THE EXPRESSION CONSTRUCT IN CELLS USED FORPRODUCTION OF r-DNA DERIVED PROTEINPRODUCTS生物技术产品的质量:从蛋白质产品中提取的r-DNA产品在细胞中表达结构的分析<1049>QUALITY OF BIOTECHNOLOGICALPRODUCTS: STABILITY TESTING OFBIOTECHNOLOGICAL/BIOLOGICALPRODUCTS生物技术(jìshù)产品的质量:生物技术/生物产品的稳定性实验<1050>VIRAL SAFETY EVALUATION OFBIOTECHNOLOGY PRODUCTS DERIVEDFROM CELL LINES OF HUMAN ORANIMAL ORIGIN从人或动物细胞中提取的生物技术产品(chǎnpǐn)的病毒安全性评估<1051>CLEANING GLASS APPARATUS玻璃(bōlí)容器的清洗<1052>BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS生物(shēngwù)技术提取法-氨基酸测定<1053>CAPILLARY ELECTROPHORESIS 毛细管电泳(diàn yǒnɡ)法<1054>BIOTECHNOLOGY-DERIVED ARTICLES—ISOELECTRIC FOCUSING生物技术提取法-等电点聚集<1055>BIOTECHNOLOGY-DERIVED ARTICLES—PEPTIDE MAPPING生物技术提取法-肽谱<1056>BIOTECHNOLOGY-DERIVED ARTICLES—POLYACRYLAMIDE GEL ELECTROPHORESIS 生物(shēngwù)技术提取法-凝胶电泳<1057>BIOTECHNOLOGY-DERIVED ARTICLES—TOTAL PROTEIN ASSAY生物(shēngwù)技术提取法-总蛋白测定<1058>ANALYTICAL INSTRUMENT QUALIFICATION 分析仪器要求(yāoqiú)<1059>EXCIPIENT PERFORMANCE 赋形剂<1061>COLOR—INSTRUMENTAL MEASUREMENT显色-仪器(yíqì)测量<1065>Ion Chromatography 离子(lízǐ)色谱法<1066>PHYSICAL ENVIRONMENTS THAT PROMOTE SAFE MEDICATION USE物理环境促使安全使用药物<1072>DISINFECTANTS AND ANTISEPTICS 消毒剂和防腐剂<1074>EXCIPIENT BIOLOGICAL SAFETY EVALUATION GUIDELINES赋形剂(辅料)生物安全性评估指导<1078>GOOD MANUFACTURING PRACTICES FOR BULK PHARMACEUTICALEXCIPIENTS批药品(yàopǐn)赋形剂的生产(shēngchǎn)管理规范<1079>Good Storage and Shipping Practices 良好(liánghǎo)的贮存与运输(yùnshū)规范(guīfàn)<1080>BULK PHARMACEUTICAL EXCIPIENTS—CERTIFICATE OF ANALYSIS 批药品赋形剂-COA<1084>GLYCOPROTEIN AND GLYCAN ANALYSIS—GENERAL CONSIDERATIONS糖蛋白和多糖分析-一般通则<1086>IMPURITIES IN DRUG SUBSTANCES AND DRUG PRODUCTS药物和药物产品中的杂质<1087>APPARENT INTRINSIC DISSOLUTION—DISSOLUTION TESTING PROCEDURESFOR ROTATING DISK AND STATIONARYDISK内部的溶出度-旋转和静止溶出检测程序?<1088>IN VITRO AND IN VIVO EVALUATION OF DOSAGE FORMS体内与体外的剂型的评估<1090>ASSESSMENT OF DRUG PRODUCTPERFORMANCE-BIOAVAILABILITY,BIOEQUIVALENCE, AND DISSOLUTION药物产品性能评估:生物利用(lìyòng)度、生物等效性和溶出<1091>LABELING OF INACTIVE INGREDIENTS 非活性成分(chéng fèn)的标示<1092>THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION溶出程序:开发(kāifā)与验证<1094>CAPSULES—DISSOLUTION TESTING AND RELATED QUALITY ATTRIBUTES胶囊-关于(guānyú)产品质量的溶出测定<1097>BULK POWDER SAMPLING PROCEDURES:粉末(fěnmò)样品取样程序<1102>IMMUNOLOGICAL TEST METHODS—GENERAL CONSIDERATIONS免疫测试方法-总则<1103>IMMUNOLOGICAL TEST METHODS—ENZYME-LINKED IMMUNOSORBENTASSAY (ELISA) 免疫学测试方法-酶联免疫吸附测定<1104>IMMUNOLOGICAL TEST METHODS—IMMUNOBLOT ANALYSIS免疫(miǎnyì)测试方法-免疫印迹法<1105>IMMUNOLOGICAL TEST METHODS—SURFACE PLASMON RESONANCE免疫测试方法-表面(biǎomiàn)等离子体共振<1106>IMMUNOGENICITY ASSAYS—DESIGN AND VALIDATION OF IMMUNOASSAYSTO DETECT ANTI-DRUG ANTIBODIES ?<1111>MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS:ACCEPTANCE CRITERIA FORPHARMACEUTICAL PREPARATIONSAND SUBSTANCES FORPHARMACEUTICAL USE非无菌产品的微生物学检查:药用制剂和制药过程(guòchéng)使用的物质接受标准<1112>MICROBIAL CHARACTERIZATION,IDENTIFICATION, AND STRAINTYPING非无菌药物产品(chǎnpǐn)水活性测定应用<1113>MICROBIOLOGICAL ATTRIBUTES OF NONSTERILE PHARMACEUTICALPRODUCTS非无菌药品(yàopǐn)中的微生物分布(fēnbù)<1115>BIOBURDEN CONTROL OF NONSTERILE DRUG SUBSTANCES AND PRODUCTS 非无菌药物和产品的生物负载(fùzài)控制<1116>MICROBIOLOGICAL CONTROL ANDMONITORING OF ASEPTICPROCESSING ENVIRONMENTS洁净的房间与其它(qítā)可控环境的微生物评估<1117>MICROBIOLOGICAL BESTLABORATORY PRACTICES 微生物最优实验室规范<1118>MONITORING DEVICES—TIME, TEMPERATURE, AND HUMIDITY监控装置-时间、温度与湿度<1119>NEAR-INFRARED SPECTROPHOTOMETRY近红外分光光度测定法<1120>Raman Spectrophotometry 拉曼分光光度测定法<1121>NOMENCLATURE命名<1125>NUCLEIC ACID-BASED TECHNIQUES—GENERAL 核酸技术(jìshù)-通则<1126>NUCLEIC ACID-BASED TECHNIQUES—EXTRACTION, DETECTION, AND SEQUENCING 核酸技术(jìshù)-提取、检测、测序<1127>NUCLEIC ACID-BASED TECHNIQUES—AMPLIFICATION 核酸(hé suān)技术-扩增<1128>NUCLEIC ACID-BASED TECHNIQUES—MICROARRAY 核酸(hé suān)技术-微阵列<1129>NUCLEIC ACID-BASED TECHNIQUES—GENOTYPING 核酸技术(jìshù)-基因分型<1130>NUCLEIC ACID-BASED TECHNIQUES—APPROACHES FOR DETECTING TRACENUCLEIC ACIDS (RESIDUAL DNATESTING)核酸技术-探测微量核酸的应用(残留DNA测试)<1136>PACKAGING AND REPACKAGING—SINGLE-UNIT CONTAINERS包装和再包装-单一容器<1151>PHARMACEUTICAL DOSAGE FORMS药物剂型<1152>ANIMAL DRUGS FOR USE IN ANIMAL FEEDS兽药在动物饲料(sìliào)中的使用<1160>PHARMACEUTICAL CALCULATIONS IN PRESCRIPTION COMPOUNDING按处方混合的药物(yàowù)的计算<1163>QUALITY ASSURANCE IN PHARMACEUTICAL COMPOUNDING按处方(chǔfāng)混合的药物的质量保证<1171>PHASE-SOLUBILITY ANALYSIS相溶解(r óngjiě)分析<1174>Powder Flow 粉末(fěnmò)流动性<1176>PRESCRIPTION BALANCES AND VOLUMETRIC APPARATUS 处方天平与容量器具<1177>Good Packaging Practices 良好的包装操作<1178>Good Repackaging Practices 良好的再包装操作<1180>HUMAN PLASMA 人血浆<1181>SCANNING ELECTRON MICROSCOPY 扫描电子显微镜<1184>SENSITIZATION TESTING 致敏测试<1191>STABILITY CONSIDERATIONS IN DISPENSING PRACTICE分装操作中稳定性考察<1195>SIGNIFICANT CHANGE GUIDE FOR BULK PHARMACEUTICAL EXCIPIENTS散装药用辅料更换指导(zhǐdǎo)原则<1197>GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS散装药用辅料良好(liánghǎo)的分装操作<1207>STERILE PRODUCT PACKAGING—INTEGRITY EVALUATION无菌产品包装-完整性评估(pínɡɡū)<1208>STERILITY TESTING—VALIDATION OF ISOLATOR SYSTEMS无菌实验(shíyàn)-隔离系统的验证<1209>STERILIZATION—CHEMICAL ANDPHYSICOCHEMICAL INDICATORS ANDINTEGRATORS灭菌(miè jūn)-化学与物理化学的指示剂以及二者的综合<1211>STERILIZATION AND STERILITY ASSURANCE OF COMPENDIAL ARTICLES 药典物品中的灭菌与灭菌保证<1216>TABLET FRIABILITY片剂的脆碎度<1217>TABLET BREAKING FORCE 片剂断裂力<1222>TERMINALLY STERILIZEDPHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE药品(yàopǐn)终端灭菌-放行(fàngxíng)参数(cānshù)<1223>VALIDATION OF ALTERNATIVEMICROBIOLOGICAL METHODS可供选择的微生物学方法(fāngfǎ)的验证<1224>TRANSFER OF ANALYTICALPROCEDURES 分析方法转移(zhuǎnyí)<1225>VALIDATION OF COMPENDIAL METHODS药典方法的验证<1226>VERIFICATION OF COMPENDIAL PROCEDURES 药典方法的确认<1227>VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES 从药物中回收微生物的验证<1229>STERILIZATION OF COMPENDIAL ARTICLES 药典灭菌过程<1229.1>STEAM STERILIZATION BY DIRECT CONTACT 直接蒸汽灭菌<1229.2>MOIST HEAT STERILIZATION OF AQUEOUS LIQUIDS 水溶液的湿热灭菌<1229.3>MONITORING OF BIOBURDEN 生物(shēngwù)负载监控<1229.4>STERILIZING FILTRATION OF LIQUIDS 溶液(róngyè)的无菌过滤器<1229.6>LIQUID-PHASE STERILIZATION 液态(yètài)灭菌<1229.7>GASEOUS STERILIZATION 气态(qìtài)灭菌<1229.8>DRY HEAT STERILIZATION 干热(ɡàn rè)灭菌<1229.10>RADIATION STERILIZATION 辐射灭菌<1230>WATER FOR HEMODIALYSIS APPLICATIONS 血液透析过程用水<1231>WATER FOR PHARMACEUTICAL PURPOSES制药用水<1234>VACCINES FOR HUMAN USE—POLYSACCHARIDE AND GLYCOCONJUGATE VACCINES人用疫苗-多糖和糖复合物疫苗<1235>VACCINES FOR HUMAN USE—GENERAL CONSIDERATIONS 人用疫苗-通则<1237>VIROLOGY TEST METHODS 病毒测试方法<1238>VACCINES FOR HUMAN USE—BACTERIAL VACCINES 人用疫苗-细菌疫苗<1240>VIRUS TESTING OF HUMAN PLASMA FOR FURTHER MANUFACTURE下一步使用(shǐyòng)人血浆的病毒测试<1241>WATER–SOLID INTERACTIONS IN PHARMACEUTICAL SYSTEMS在药物(yàowù)系统中水与固体的相互作用<1251>WEIGHING ON AN ANALYTICAL BALANCE关于分析天平(fēn xī tiān pínɡ)的称重<1265>Written Prescription Drug Information-Guidelines 书面(shūmiàn)的处方药信息-指南<1285>PREPARATION OF BIOLOGICALSPECIMENS FOR HISTOLOGIC ANDIMMUNOHISTOCHEMICAL ANALYSIS 为了(wèi le)组织和免疫组织分析的生物标本制备<1285.1>HEMATOXYLIN AND EOSIN STAINING OF SECTIONED TISSUE FORMICROSCOPIC EXAMINATION显微镜观察用苏木精和伊红染色的切片<1601>PRODUCTS FOR NEBULIZATION—CHARACTERIZATION TESTS 产品雾化状态-性状描述<1644>THEORY AND PRACTICE OFELECTRICAL CONDUCTIVITYMEASUREMENTS OF SOLUTIONS 溶液电导(diàn dǎo)值测量方法的理论与实践<1660>EVALUATION OF THE INNER SURFACE DURABILITY OF GLASS CONTAINERS 玻璃(bō lí)容器内表面耐久性评估<1724>SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS 半固态药物(yàowù)产品-性能测试<1736>APPLICATIONS OF MASSSPECTROMETRY 质谱应用(yìngyòng)<1761>APPLICATIONS OF NUCLEARMAGNETIC RESONANCESPECTROSCOPY核磁共振(hé cíɡònɡ zhèn)光谱应用<1787>MEASUREMENT OF SUBVISIBLEPARTICULATE MATTER INTHERAPEUTIC PROTEIN INJECTIONS 用显微镜测量方法测量治疗性蛋白注射剂的不溶性微粒<1788>METHODS FOR THE DETERMINATION OF PARTICULATE MATTER ININJECTIONS AND OPHTHALMICSOLUTIONS注射剂和眼用溶液的不溶性微粒测定(cèdìng)的方法选择<1852>ATOMIC ABSORPTION SPECTROSCOPY—THEORY AND PRACTICE原子吸收光谱(xī shōu ɡuānɡ pǔ)-理论与实践<1853>FLUORESCENCE SPECTROSCOPY—THEORY AND PRACTICE荧光光谱-理论(lǐlùn)与实践<1854>MID-INFRARED SPECTROSCOPY—THEORY AND PRACTICE中红外光谱(guāngpǔ)-理论与实践<1857>ULTRAVIOLET-VISIBLESPECTROSCOPY—THEORY ANDPRACTICE紫外可见(kějiàn)光谱-理论与实践<1911>RHEOMETRY 流变测定Dietary Supplements营养补充剂General Tests and Assays 一般检查法与测定法<2021>MICROBIAL ENUMERATION TESTS—NUTRITIONAL AND DIETARY SUPPLEMENTS…3080微生物数量实验-营养(yíngy ǎng)与食品添加剂<2022>MICROBIOLOGICAL PROCEDURES FOR ABSENCE OF SPECIFIED MICROORGANISMS—NUTRITIONAL AND DIETARY SUPPLEMENTS (3083)不得(bu de)检出特定微生物的程序-营养与营养(yíngy ǎng)补充剂<2023>MICROBIOLOGICAL ATTRIBUTES OF NONSTERILE NUTRITIONAL AND DIETARY SUPPLEMENTS……3087非无菌的营养与食品(shípǐn)添加剂中的微生物分布<2040>DISINTEGRATION AND DISSOLUTION OF DIETARY SUPPLEMENTS (3089)食品(shípǐn)添加剂的崩解与溶出<2091>WEIGHT VARIATION OF DIETARY SUPPLEMENTS……3092食品添加剂的重量差异<2750>MANUFACTURING PRACTICES FOR DIETARY SUPPLEMENTS (3093)食品添加剂的生产操作内容总结(1)USP38-通用章节目录。

一种快速测定人血浆中帕罗西汀血药浓度的方法[发明专利]

一种快速测定人血浆中帕罗西汀血药浓度的方法[发明专利]

专利名称:一种快速测定人血浆中帕罗西汀血药浓度的方法专利类型:发明专利
发明人:孙冬雪,王迪,王敏
申请号:CN201910897041.8
申请日:20190923
公开号:CN112540129A
公开日:
20210323
专利内容由知识产权出版社提供
摘要:本发明属分析化学领域,本发明公开了一种UPLC‑MS/MS法测定人血浆中帕罗西汀的方法,该方法采用十八烷基硅烷键合硅胶为填料的色谱柱,以甲酸溶液‑有机溶剂流动相体系,采用梯度洗脱的方法检测人血浆中帕罗西汀的血药浓度,从而有效为帕罗西汀生物等效性检测方法提供方法依据,实现帕罗西汀口崩片的体内药代动力学分析。

本发明方法专属性强,灵敏度高,快速,操作简便。

申请人:北京万全德众医药生物技术有限公司
地址:102206 北京市昌平区生命科学园博达大厦南楼(万全)
国籍:CN
更多信息请下载全文后查看。

GSK2190915-sodium-salt-SDS-MedChemExpress

GSK2190915-sodium-salt-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Oct.-11-2018Print Date:Oct.-11-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GSK2190915 (sodium salt)Catalog No. :HY-15874ACAS No. :1196070-26-41.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GSK-2190915A;Fiboflapon sodium;AM-803 sodiumFormula:C38H42N3NaO4SMolecular Weight:659.81CAS No. :1196070-26-44. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

直接胆红素测定试剂盒(钒酸盐氧化法)产品技术要求baiding

直接胆红素测定试剂盒(钒酸盐氧化法)产品技术要求baiding

直接胆红素测定试剂盒(钒酸盐氧化法)适用范围:本试剂用于体外定量测定人血清中直接胆红素的含量。

1.产品型号/规格产品组成:2.1 外观2.1.1 试剂1为无色透明液体,无混浊,无未溶解物。

2.1.2 试剂2为浅黄色透明液体,无混浊,无未溶解物。

2.1.3 校准品为浅黄色冻干粉,溶解后为黄色液体,无未溶解物。

2.1.4 标签内容清晰,字迹牢固不易脱落。

2.2 试剂装量液体试剂的净含量不少于标示值。

2.3 含水量校准品冻干粉含水量≤3%。

2.4 试剂空白吸光度A≤0.080(光径1.0cm,546nm±20nm 波长)。

2.5 分析灵敏度测定20μmol/L样本,吸光度变化在0.02~0.04范围内。

2.6 线性区间2.6.1 [1,342]μmol/L。

在规定的线性范围内,测定值与样本浓度值的相关系数(r)应不低于0.990。

2.6.2 [1,10]μmol/L范围内,线性绝对偏差应不超过±1μmol/L;(10,342]μmol/L范围内,线性相对偏差应不超过±10%。

2.7 精密度2.7.1 重复性变异系数CV≤5.0%。

2.7.2 批内瓶间差试剂盒内校准品瓶间差CV≤5.0%。

2.7.3 批间差批间相对极差≤6.0%。

2.8 准确度回收率在(100±10)%范围内。

2.9 稳定性2.9.1 校准品冻干粉复溶后在2℃~8℃避光保存稳定4天,测定结果应符合2.8要求。

2.9.2 原装试剂2℃~8℃保存,有效期12个月,有效期满后2个月内测定结果应符合2.1、2.4、2.5、2.6、2.7.1、和2.8要求。

《2024年鬼臼苦素对三阴性乳腺癌MDA-MB-231细胞增殖的抑制作用及其作用机制的研究》范文

《2024年鬼臼苦素对三阴性乳腺癌MDA-MB-231细胞增殖的抑制作用及其作用机制的研究》范文

《鬼臼苦素对三阴性乳腺癌MDA-MB-231细胞增殖的抑制作用及其作用机制的研究》篇一一、引言三阴性乳腺癌(TNBC)是一种恶性程度高、预后较差的乳腺癌亚型,因其缺乏有效的治疗靶点而成为乳腺癌治疗的难题。

近年来,天然药物在抗癌治疗中的潜力逐渐受到关注,其中鬼臼苦素作为一种具有抗肿瘤活性的化合物,其对三阴性乳腺癌的治疗效果尤其引人关注。

本研究旨在探讨鬼臼苦素对三阴性乳腺癌MDA-MB-231细胞增殖的抑制作用及其作用机制。

二、材料与方法1. 材料鬼臼苦素、MDA-MB-231细胞株、DMEM培养基、胎牛血清、MTT试剂等。

2. 方法(1)细胞培养与处理:将MDA-MB-231细胞在DMEM培养基中培养,并分别用不同浓度的鬼臼苦素处理细胞。

(2)细胞增殖实验:采用MTT法检测鬼臼苦素对MDA-MB-231细胞增殖的影响。

(3)流式细胞术:检测细胞周期、凋亡等相关指标。

(4) Western blot:检测相关蛋白的表达情况。

三、实验结果1. 鬼臼苦素对MDA-MB-231细胞增殖的抑制作用实验结果显示,鬼臼苦素能显著抑制MDA-MB-231细胞的增殖,且随着药物浓度的增加,抑制作用逐渐增强。

2. 鬼臼苦素对MDA-MB-231细胞周期的影响流式细胞术结果显示,鬼臼苦素能将MDA-MB-231细胞阻滞在S期,并降低S期细胞比例,同时增加G0/G1期细胞比例。

3. 鬼臼苦素诱导MDA-MB-231细胞凋亡的作用流式细胞术检测显示,鬼臼苦素能显著诱导MDA-MB-231细胞凋亡,并呈剂量依赖性。

4. 鬼臼苦素作用机制的相关蛋白表达情况Western blot结果显示,鬼臼苦素能上调p53、p21等抑癌基因的表达,同时下调Bcl-2等抗凋亡蛋白的表达,从而发挥其抗肿瘤作用。

四、讨论本研究表明,鬼臼苦素能显著抑制三阴性乳腺癌MDA-MB-231细胞的增殖,其作用机制可能与以下几个方面有关:一是通过阻滞细胞周期于S期,降低S期细胞比例;二是通过诱导细胞凋亡,增加凋亡细胞比例;三是通过上调抑癌基因的表达和下调抗凋亡蛋白的表达,从而发挥抗肿瘤作用。

甲醇中奥沙西泮-d5同位素 -回复

甲醇中奥沙西泮-d5同位素 -回复

甲醇中奥沙西泮-d5同位素-回复什么是甲醇中奥沙西泮d5同位素?甲醇中奥沙西泮d5同位素是指在甲醇中存在着奥沙西泮的一种同位素。

奥沙西泮是一种广泛使用的药物,常用于治疗焦虑症和睡眠障碍。

它属于苯二氮䓬类药物,通过作用于中枢神经系统产生镇静、抗焦虑和催眠效果。

甲醇则是一种有机溶剂,常用于实验室中的化学反应和工业中的溶剂。

为什么需要甲醇中奥沙西泮d5同位素?甲醇中奥沙西泮d5同位素的存在主要是为了研究奥沙西泮的代谢和药物动力学过程。

在药物研发和临床应用中,了解药物代谢和动力学特性对于确定最佳剂量、剂型和给药途径非常重要。

同位素标记技术可以提供有关药物在体内分布、代谢和消除的定量信息,从而帮助改善药物疗效和减少不良反应。

如何制备甲醇中奥沙西泮d5同位素?制备甲醇中奥沙西泮d5同位素需要从商业来源购买奥沙西泮的同位素标记药物。

d5表示奥沙西泮的某些氢原子被其同位素氘(D)所取代。

这种同位素标记的奥沙西泮通常是以甲醇溶剂中的形式提供。

购买到同位素标记的奥沙西泮后,可以将其直接溶解在甲醇中,制备成甲醇中奥沙西泮d5同位素的溶液。

这样就得到了可以用于研究的甲醇中奥沙西泮d5样品。

甲醇中奥沙西泮d5同位素的应用甲醇中奥沙西泮d5同位素在药物代谢动力学研究中有着广泛的应用。

使用同位素标记技术,可以通过分析体内标记药物和其代谢产物中同位素的比例来确定药物的代谢速率、药物清除率和药物在体内的分布。

这些数据对于评估药物的疗效和安全性非常重要,并且可以用于优化药物治疗方案。

此外,甲醇中奥沙西泮d5同位素还可以用于研究药物与其他药物或化合物的相互作用。

通过将同位素标记的奥沙西泮与其他药物或化合物一起使用,可以了解它们之间的相互作用对代谢和药效的影响。

总结甲醇中奥沙西泮d5同位素是一种在甲醇溶剂中存在的奥沙西泮同位素。

该同位素的制备和应用主要用于药物代谢动力学研究,能够提供药物在体内代谢、分布和消除的定量信息。

同位素标记技术在药物研发和临床应用中起着重要的作用,帮助优化药物治疗方案,提高药物的疗效和安全性。

总胆红素钒酸盐氧化法试剂盒标准操作程序

总胆红素钒酸盐氧化法试剂盒标准操作程序

总胆红素(钒酸盐氧化法)试剂盒标准操作程序1.摘要本试剂盒供医疗机构用于体外定量测定人血清样本中总接胆红素的含量。

2.适用范围程序适用于AU5811自动生化分析仪检测血清样本中总接胆红素的含量。

3.职责使用AU5811自动生化分析仪进行测定总接胆红素浓度的工作人员要严格按照本SOP程序进行,室负责人监督管理;本SOP的改动,可由任一使用本SOP的工作人员提出,并报经生化室负责人、科主任签字批准生效。

4.检测方法上海科华生物工程股份有限公司生产的总接胆红素(钒酸盐氧化法)试剂盒采用的是钒酸盐氧化法。

5.原理pH3.0左右,在起加速剂作用的表面活性剂的条件下,能够增进未结合胆红素的溶解度,样本中的总胆红素被钒酸盐氧化成胆绿素。

与此同时,胆红素特有的黄色也随之消失。

所以通过测定胆红素氧化前后吸光度的变化,就可以计算出样本中的总胆红素的浓度。

6.仪器AU5811自动生化分析仪7.试剂1.1试剂来源:上海科华生物工程股份有限公司提供1.2试剂瓶内主要成分:R1:枸橼酸盐缓冲液(pH2.6)、表面活性剂;R2:磷酸盐缓冲液、偏钒酸盐1.3试剂稳定性:试剂于2℃-8℃避光保存,有效期为一年2.标准品和质量控制2.1校准程序:使用科华公司的校准品对自动分析仪进行校准。

按照公司标准品使用要求,并以9g/L氯化钠溶液或去离子水为空白,经校准测定,仪器自动对标准品通过合适的数学模型绘制校准曲线。

2.2质控品:罗氏公司提供的生化复合定值质控血清作为室内质控品。

每日在测定前做一次质控加试剂后做一次质控。

该质控品为干粉包装,在2-8℃冰箱可稳定到失效期,使用前用5ml去离子水复溶,待质控物充分溶解(大约30分钟)后使用。

2.3质控数据管理:按程序对检验后的质控后结果进行转换,及时质控数据进行分析处理,如出现失控值,应及时分析失控原因,并填写好相关失控记录。

2.4质控判断规则:按《Westgard多规则质控方法测定标准操作程序》2.5室间质评:分别参加河北省室间质评,对回报的室间质评结果按《室间质量评价程序》进行处理。

GSK2190915_sodium_salt_DataSheet_MedChemExpress

GSK2190915_sodium_salt_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:GSK2190915(AM–803; Fiboflapon) sodium salt is a potent FLAP(5–Lipoxygenase–activating protein) inhibitor with binding IC50 of 2.9nM.IC50 value: 76 nM (inhibition of LTB4 in human blood 5 h incubation) [1]Target: FLAP inhibitorGSK2190915 exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. GSK2190915 also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model [1]. Oral administration of AM803 (1 mg/kg)resulted in sustained inhibition of ex vivo ionophore–challenged whole blood LTB4 biosynthesis with >90% inhibition for up to 12 h and an EC50 of approximately 7 nM. When rat lungs were challenged in vivo with calcium–ionophore, AM803 inhibited LTB4 and cysteinyl leukotriene (CysLT) production with ED50s of 0.12 mg/kg and 0.37 mg/kg, respectively. The inhibition measured 16 hfollowing a single oral dose of 3 mg/kg was 86% and 41% for LTB4 and CysLTs, respectively. In an acute inflammation setting, AM803dose–dependently reduced LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection.Finally, AM803 increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF) [2].References:[1]. Stock NS, et al. 5–Lipoxygenase–activating protein (FLAP) inhibitors. Part 4: development of3–[3–tert–butylsulfanyl–1–[4–(6–ethoxypyridin–3–yl)benzyl]–5–(5–methylpyridin–2–ylmethoxy)–1H–indol–2–yl]–2,2–dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. J Med Chem. 2011 Dec 8;54(23):8013–29.[2]. Lorrain DS, et al. Pharmacology of AM803, a novel selective five–lipoxygenase–activating protein (FLAP) inhibitor in rodent models of acute inflammation.Eur J Pharmacol. 2010 Aug 25;640(1–3):211–8.Product Name:GSK2190915 (sodium salt)Cat. No.:HY-15874A CAS No.:1196070-26-4Molecular Formula:C 38H 42N 3NaO 4S Molecular Weight:659.81Target:FLAP Pathway:Immunology/Inflammation Solubility:DMSO: ≥ 32 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

高碘酸钾法测定去甘油红细胞的甘油残留量

高碘酸钾法测定去甘油红细胞的甘油残留量

高碘酸钾法测定去甘油红细胞的甘油残留量
李素敏;蔡计荣
【期刊名称】《中国输血杂志》
【年(卷),期】1999(12)3
【总页数】1页(P179-179)
【关键词】高碘酸钾;红细胞;甘油;残留量
【作者】李素敏;蔡计荣
【作者单位】河北省血液中心
【正文语种】中文
【中图分类】R392.33
【相关文献】
1.高碘酸钠法检测冰冻解冻去甘油红细胞中甘油残留量方法的探讨 [J], 杨夏;赵磊;白旭华
2.红细胞处理仪洗涤去甘油化与手工洗涤去甘油化效果比较 [J], 武晓林;冯庆功;张维
3.冰冻红细胞甘油化与去甘油化的改进 [J], 张成松
4.甘油化时滴速对冰冻解冻去甘油红细胞质量影响 [J], 柴婷婷
5.甘油化冷冻红细胞复苏、去甘油的方法改进 [J], 赵素珍;刘杰;张丽;张立新;张春燕
因版权原因,仅展示原文概要,查看原文内容请购买。

同位素稀释气相色谱-质谱法快速测定酱油中3-氯-1,2-丙二醇量

同位素稀释气相色谱-质谱法快速测定酱油中3-氯-1,2-丙二醇量

同位素稀释气相色谱-质谱法快速测定酱油中3-氯-1,2-丙二醇量王悦宏;闫吉昌;刘俊会;徐锐;薛静;王卫华;石金娥;陈大伟;闫福成【期刊名称】《分析化学》【年(卷),期】2007(35)11【摘要】采用同位素稀释气相色谱-质谱联用(GC-MS)法,快速测定酱油中3-氯-1,2-丙二醇(3-MCPD)的含量.试样中加入3-氯-1,2-丙二醇的氘代同位素作为内标,经超声混匀后加入到自行填装的弗罗里硅土柱中,以乙醚洗脱,洗脱液经氮气吹干后在正己烷溶剂中进行衍生化,衍生化试剂采用七氟丁酰咪唑.GC-MS采用选择离子监测(SIM)模式进行定性定量分析.结果表明,本方法的添加回收率为95.0%~101.0%;相对标准偏差为3.2%~4.8%;检出限达到0.010 mg/kg.本方法步骤简单,溶剂用量少,定性定量准确可靠.可快速测定酱油等调味品中3-氯-1,2-丙二醇的含量.【总页数】4页(P1657-1660)【作者】王悦宏;闫吉昌;刘俊会;徐锐;薛静;王卫华;石金娥;陈大伟;闫福成【作者单位】东北师范大学城市与环境学院,长春,130024;吉林省产品质量监督检验院,长春,130022;东北师范大学城市与环境学院,长春,130024;吉林省产品质量监督检验院,长春,130022;国家标准物质研究中心,北京,100013;东北师范大学城市与环境学院,长春,130024;国家标准物质研究中心,北京,100013;东北师范大学城市与环境学院,长春,130024;东北师范大学城市与环境学院,长春,130024;东北师范大学城市与环境学院,长春,130024【正文语种】中文【中图分类】O6【相关文献】1.固相萃取-气相色谱-三重四级杆串联质谱法测定酱油中3-氯-1,2-丙二醇 [J], 户庆云;李达;张琦2.气相色谱-三重四级杆串联质谱法快速测定酱油中3-氯-1,2-丙二醇含量 [J], 宗万里;3.固相萃取-气相色谱-质谱法测定酱油中3-氯-1,2-丙二醇 [J], 刘宝峰;刘平平;谢文兵4.气相色谱-三重四级杆串联质谱法快速测定酱油中3-氯-1,2-丙二醇含量 [J], 宗万里5.气相色谱-质谱法测定酱油中3-氯-1,2-丙二醇 [J], 吴伟峰;严文昭因版权原因,仅展示原文概要,查看原文内容请购买。

植物金属硫蛋白提取液配方对镉中毒大鼠抗氧化作用的研究

植物金属硫蛋白提取液配方对镉中毒大鼠抗氧化作用的研究

植物金属硫蛋白提取液配方对镉中毒大鼠抗氧化作用的研究杜岩岩;龚建福;刘继文【期刊名称】《新疆医科大学学报》【年(卷),期】2010(033)005【摘要】目的研究新疆地产植物金属硫蛋白(MT)提取液配方对镉中毒的预防及治疗作用,为有效保护重金属作业人群,开发新型重金属中毒拮抗剂--金属硫蛋白提供理论依据.方法选择Wistar大鼠60只,分为阴性对照组,阳性中毒组,两个预防组及两个治疗组;用CdCl2进行染毒,采用前期试验所得到的植物金属硫蛋白提取液配方干预,预防组大鼠在镉中毒处理前两周以提取液进行干预,治疗组大鼠在镉中毒处理后两周以提取液进行干预.以血清超氧化物歧化酶(SOD)活力、谷胱甘肽过氧化物酶(GSH-Px)活力和丙二醛(MDA)含量为分析指标,分析MT提取液配方对镉中毒的治疗及预防效果.结果 (1)预防组,治疗组对血清SOD活力、GSH-Px活力、MDA 含量的影响均与阳性对照组差异有统计学意义(P>0.05);(2)高剂量金属硫蛋白干预组MDA含量与治疗组差异有统计学意义(P<0.05);结论新疆地产植物金属硫蛋白提取液配方对镉中毒大鼠血清脂质过氧化损伤有一定的修复作用,且早期应用效果更好.【总页数】3页(P501-502,506)【作者】杜岩岩;龚建福;刘继文【作者单位】新疆医科大学公共卫生学院劳动卫生与环境卫生学教研室,新疆,乌鲁木齐,830011;新疆医科大学公共卫生学院劳动卫生与环境卫生学教研室,新疆,乌鲁木齐,830011;新疆医科大学公共卫生学院劳动卫生与环境卫生学教研室,新疆,乌鲁木齐,830011【正文语种】中文【中图分类】R-33【相关文献】1.急性镉中毒大鼠肝脏金属硫蛋白的免疫电镜定位 [J], 周雍;金慧英;胡惠民;于秉学;魏尧梅;郑尊2.金属硫蛋白提取液配方对镉中毒小鼠血液脂质过氧化的影响 [J], 李砥;龚建福;刘继文3.新疆部分植物金属硫蛋白提取液对镉中毒小鼠肾损伤的修复作用 [J], 马晓媛;龚建福;刘继文4.新疆巴楚蘑菇、平菇中金属硫蛋白提取液对镉中毒小鼠脏器的修复作用 [J], 陈勇;龚建福;刘继文5.金属硫蛋白提取液对镉中毒小鼠脂质过氧化损伤的修复作用 [J], 于立博;龚建福;黄贤仪因版权原因,仅展示原文概要,查看原文内容请购买。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GSK2190915 (sodium salt)Catalog No. :HY-15874ACAS No. :1196070-26-41.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:GSK⁻2190915A; Fiboflapon sodium; AM⁻803 sodiumFormula:C38H42N3NaO4SMolecular Weight:659.81CAS No. :1196070-26-44. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

相关文档
最新文档